Figure 2From: Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapyPrimary axis: predicted pooled mean daily utility for study period, stratified by treatment arm (GRAZAX®, red line; placebo, green line [with 95% CI]) . Secondary axis: proportion of study sample with observations by day of pollen season (GRAZAX®, red bars; placebo, green bars).Back to article page